Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks (NYSE:DNA) reported first-half 2026 cash burn of $93M, down 3% from $96M a year earlier. Management said Q1 cash burn included a $14M Google Cloud payment tied to an amended 2025 commitment that cut future minimums by over $100M and extended the term to six years. Ginkgo expanded its Nebula lab to 105 racks and raised $17M via an ATM.
Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991earningspr.htm EX-99.1 Document Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland Ginkgo provides an update on its second quarter financial
Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. dna-20260611 0001830214 FALSE 0001830214 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________ FORM 8-K ______________________________________________________________ CURRENT RE
Over the past 7 days, alphai's AI scored 2 news stories mentioning DNA (Ginkgo Bioworks Holdings, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent DNA coverage spans technology, earnings and corporate actions.
In the last 30 days, DNA insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($6K). The most active reporter was Coen Steven P., See remarks, with 1 filing.
The call adds incremental operating and financing details that can shift near-term cash runway expectations and validate autonomous-lab commercialization progress.
The filing provides fresh quarterly financials plus a reaffirmed 2026 cash-burn range, which can drive near-term valuation and risk appetite for DNA.
This is a corporate governance/AGM outcome filing; it confirms board composition and auditor ratification but does not disclose new operating or financial guidance.
Story reinforces Ginkgo’s positioning in automated bioengineering, but provides no new financial datapoints or contract/drug milestones.
Story highlights platform progress in autonomous biotech experimentation, which can support long-term sentiment but lacks near-term financial catalysts.
alphai scores every news story that mentions DNA with an AI model for sentiment and relevance, and aggregates insider trades from Ginkgo Bioworks Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ginkgo Bioworks (NYSE:DNA) reported first-half 2026 cash burn of $93M, down 3% from $96M a year earlier. Management said Q1 cash burn included a $14M Google Cloud payment tied to an amended 2025 commitment that cut future minimums by over $100M and extended the term to six years. Ginkgo expanded its Nebula lab to 105 racks and raised $17M via an ATM.
6 min readGinkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991earningspr.htm EX-99.1 Document Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland Ginkgo provides an update on its second quarter financial
6 min readGinkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. dna-20260611 0001830214 FALSE 0001830214 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________ FORM 8-K ______________________________________________________________ CURRENT RE
2 min readNPR reports that Ginkgo Bioworks in Boston is building an “autonomous lab” where AI and robots handle tasks such as pipetting, scheduling experiments, and designing work in areas including drug discovery, fertilizer microbes, and protein engineering. Founders Jason Kelly and Reshma Shetty say AI is increasingly generating hypotheses, including via an OpenAI collaboration. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.
7 min readNPR reports that Ginkgo Bioworks in Boston is building an “autonomous lab” where AI directs robots to run experiments, including drug discovery, fertilizer microbes, and protein design. Founders Jason Kelly and Reshma Shetty say AI is moving from recipe-following to generating hypotheses, including a ChatGPT/OpenAI collaboration. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.
6 min readNPR reports that Ginkgo Bioworks in Boston is building an “autonomous lab” where AI directs robots to run experiments, including drug discovery, microbes for fertilizer, and protein design. Founders say AI is shifting work from manual lab time to overnight robot execution, including AI-written lab notebook entries. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.
7 min readNPR reports that Ginkgo Bioworks in Boston is building an “autonomous lab” where AI and robots handle tasks such as pipetting, scheduling experiments, and designing drug, fertilizer, and protein-related work. Founders say AI is moving from robot instructions to AI-written lab notebook entries, including an OpenAI GPT-5 collaboration. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.
7 min readNPR reports that Ginkgo Bioworks in Boston is developing an “autonomous lab” where AI directs robots to run experiments, including drug discovery, fertilizer microbes, and protein design. Founders say AI is moving from automating tasks to generating hypotheses, including an OpenAI collaboration using GPT‑5 to design a cell-free protein synthesis reaction. Stanford’s Drew Endy warns of biosecurity and skills-loss risks.
6 min readNPR reports that researchers, including Ginkgo Bioworks in Boston, are building “autonomous labs” where AI and robots run experiments, design protocols, and even generate hypotheses. The company’s founders say automation reduces hours of manual work. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how as access broadens.
7 min readNPR reports that researchers, including Ginkgo Bioworks in Boston, are building “autonomous labs” where AI-directed robots handle tasks such as pipetting, scheduling experiments, and designing drug, fertilizer, and protein research. Founders say AI is moving from automating steps to generating hypotheses, including via an OpenAI collaboration. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.
9 min read
